Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.39 |
| ▸ | FPR2 | P25090 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4077829 | 0.96 | MAT2A (0.43) | MAT2AELANETSHRPOLBACVR1 | |
| SCHEMBL7745809 | 0.96 | MAT2A (0.43) | MAT2AELANETSHRPOLBACVR1 | |
| SCHEMBL7752199 | 0.93 | ELANE (0.42) | MAT2AELANETSHRPOLBACVR1 | |
| SCHEMBL4078860 | 0.92 | ACVR1 (0.43) | MAT2AELANETSHRPOLBACVR1 | |
| SCHEMBL7749860 | 0.92 | ACVR1 (0.43) | MAT2AELANETSHRPOLBACVR1 | |
| SCHEMBL7751002 | 0.92 | MAT2A (0.43) | MAT2AELANETSHRPOLBACVR1 | |
| SCHEMBL7751014 | 0.91 | MAT2A (0.41) | MAT2AELANETSHRPOLBACVR1 | |
| SCHEMBL7751033 | 0.90 | MAT2A (0.42) | MAT2AELANETSHRPOLBACVR1 | |
| SCHEMBL4254009 | 0.90 | MAT2A (0.42) | MAT2AELANETSHRPOLBACVR1 | |
| SCHEMBL4083507 | 0.89 | MAT2A (0.43) | MAT2AELANETSHRPOLBACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598252-B2 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | MAT2A 285/4885ELANE 1552/4885TSHR 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.